Method of efficiently establishing induced pluripotent stem cells
The present invention provides a method of improving the efficiency of establishment of induced pluripotent stem (iPS) cells by inhibiting p38 function in the step of somatic cell nuclear reprogramming. The 38 function can be inhibited by bringing an inhibitor selected from the group consisting of (1) a chemical inhibitor of p38 (2) a dominant negative mutant of p38 or a nucleic acid that encodes the same, (3) a nucleic acid selected from the group consisting of siRNAs and shRNAs targeted to p38 and DNAs that encode the same and (4) an inhibitor of p38 pathway into contact with a somatic cell and the like. The present invention also provides an agent for improving the efficiency of establishment of induced pluripotent stem cells, which contains an inhibitor of p38 function, particularly an inhibitor selected from the group consisting of (1) a chemical inhibitor of p38 (2) a dominant negative mutant of p38 or a nucleic acid that encodes the same, (3) a nucleic acid selected from the group consisting of siRNAs and shRNAs targeted to p38 and DNAs that encode the same and (4) an inhibitor of p38 pathway. Moreover, the present invention provides a production method of iPS cells, which includes bringing a nuclear reprogramming substance and an inhibitor of p38 function into contact with a somatic cell.
1. A method of improving the efficiency of establishment of induced pluripotent stem cells, consisting essentially of a step of introducing into a somatic cell into which a nuclear reprogramming substance is simultaneously introduced or has been previously introduced within the past 5 days
(i) a chemical inhibitor of p38, (ii) a dominant negative mutant of p38 or a DNA that encodes the same, or (iii) a nucleic acid selected from the group consisting of p38 siRNAs, p38 shRNAs and DNAs that encode the same,
thereby improving the efficiency of establishment of induced pluripotent stem cells.
2. The method according to claim 1 , wherein a chemical inhibitor of p38 is introduced into the somatic cell.
3. The method according to claim 2 , wherein the chemical inhibitor of p38 is at least one substance selected from the group consisting of SB202190 and SB239063.
4. The method according to claim 1 , wherein a dominant negative mutant of p38 or a DNA that encodes the same is introduced into the somatic cell.
5. The method according to claim 1 , wherein a nucleic acid selected from the group consisting of p38 siRNAs, p38 shRNAs and DNAs that encode the same is introduced into the somatic cell.
6. A method of producing induced pluripotent stem cells, consisting essentially of the following steps:
introducing a nuclear reprogramming substance into a somatic cell, and
introducing into the somatic cell a p38 inhibitor selected from (i) a chemical inhibitor of p38 , (ii) a dominant negative mutant of p38 or a DNA that encodes the same, and (iii) a nucleic acid selected from the group consisting of p38 siRNAs, p38 shRNAs, and DNAs that encode the same, wherein introducing the p38 inhibitor occurs simultaneously with, or within 5 days of, introducing the nuclear reprogramming substance,
thereby producing induced pluripotent stem cells.
7. The method according to claim 6 , wherein the p38 inhibitor is a chemical inhibitor of p38.
8. The method according to claim 7 , wherein the chemical inhibitor of p38 is at least one substance selected from the group consisting of SB202190 and SB239063.
9. The method according to claim 6 , wherein the p38 inhibitor is a dominant negative mutant of p38 or a DNA that encodes the same.
10. The method according to claim 6 , wherein the p38 inhibitor is a nucleic acid selected from the group consisting of p38 siRNAs, p38 shRNAs, and DNAs that encode the same.
11. The method according to claim 6 , wherein the nuclear reprogramming substances are Oct3/4, Klf4 and Sox2, or nucleic acids that encode the same.
12. The method according to claim 6 , wherein the nuclear reprogramming substances are Oct3/4, Klf4, Sox2 and at least one selected from the group consisting of (a) c-Myc or L-Myc, (b) Nanog, (c) Lin28 or Lin28B, and (d) Glis1, or nucleic acids that encode the same.
13. The method according to claim 1 , wherein the induced pluripotent stem cell is a human cell.
14. The method according to claim 2 , wherein the induced pluripotent stem cell is a human cell.
15. The method according to claim 14 , wherein the chemical inhibitor of p38 is SB202190.
16. The method according to claim 6 , wherein the induced pluripotent stem cell is a human cell.
17. The method according to claim 7 , wherein the induced pluripotent stem cell is a human cell.
18. The method according to claim 17 , wherein the chemical inhibitor of p38 is SB202190.